It was announced by the U.S. Food and Drug Administration(FDA) will be amending the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine. The third dose will be allocated for immunocompromised individuals. There is an estimated 3% of people in America that are considered immunocompromised individuals.
“Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19, as we’ve previously stated, other individuals who are fully vaccinated are adequately protected and do not need an additional dose of COVID-19 vaccine at this time. The FDA is actively engaged in a science-based, rigorous process with our federal partners to consider whether an additional dose may be needed in the future. “- Janet Woodcock, M.D., FDA Commissioner